Alex Blyth
Founder and Chief Executive Officer of LIfT BioSciences.
Serial entrepreneur with 15 years’ experience in commercialising novel biopharma assets and strategy consulting, having advised teams and led the strategic planning for bringing to market over 50 assets for companies like Pfizer, Allergan, abbVie, Amgen, Shire, Takeda, GSK & Sanofi. Founded the company after losing his mother to Pancreatic Cancer, and seeing a new way to beat cancer by utilising the innate immune system.
Visit website: https://www.liftbiosciences.com/our-staff
See also: LIfT BioSciences - Biotechnology company that develops a portfolio of potentially life-saving immuno-oncology cell therapies
Details last updated 01-May-2020
Alex Blyth News
LIfT BioSciences cell therapy infiltrates pancreatic tumour in mice models
LIfT BioSciences - 09-Nov-2020
N-LIfT is an allogenic cell therapy which recruits patient's own immune cells against cancers
Read more...Radical new cancer treatment to be trialled next year
ITV News - 24-Nov-2017
Uses cancer-killing cells from people with the strongest immune systems. Neutrophil cells form p...
Read more...